Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Non Operating Income (2019 - 2025)

Rein Therapeutics filings provide 7 years of Non Operating Income readings, the most recent being -$20000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 95.16% year-over-year to -$20000.0, compared with a TTM value of $48000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $48000.0, changed N/A over the prior year.
  • Non Operating Income hit -$20000.0 in Q4 2025 for Rein Therapeutics, up from -$89000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $336000.0 in Q4 2022, with the low at -$413000.0 in Q4 2024.
  • Median Non Operating Income over the past 5 years was $81500.0 (2021), compared with a mean of $75055.6.
  • The sharpest move saw Non Operating Income surged 3800.0% in 2023, then plummeted 742.86% in 2024.
  • Year by year, Non Operating Income stood at $71000.0 in 2021, then soared by 373.24% to $336000.0 in 2022, then plummeted by 114.58% to -$49000.0 in 2023, then crashed by 742.86% to -$413000.0 in 2024, then surged by 95.16% to -$20000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$20000.0, -$89000.0, and $49000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.